Mark Milton

Mark Milton

Company: Lake Boon Pharmaceutical Consulting

Job title: Principal


Mark retired in 2022 after 31 years in the Pharmaceutical Industry, most recently working for Novartis where he provided support to biodistribution and immunogenicity assessments for Gene Therapies.


Detecting Pre-Existing Immunity to AAV Gene Therapies 11:00 am

One of the inherent challenges to effective AAV gene therapy treatment is the prior exposure and neutralizing antibody (NAb) generation in a large number of target populations. The methods used for testing for seropositivity prior to transfer remains a hotly-debated topic, with no universal test or titer currently deployed as an industry standard for detecting…Read more

day: Pre-Conference Day

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.